Gene therapy

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

A mother’s perspective on Sarepta’s gene therapy halt

Adam's Take Adam Feuerstein

STAT Plus: Why Sarepta may not survive its current gene therapy crisis 

Opinions+ Yvonne Greenstreet

Alnylam CEO: Congress must pass the MINI Act to protect future biotech breakthroughs

First Opinion Jennifer Handt and Kelly Maynard

STAT Plus: We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress

Adam's Take Adam Feuerstein

STAT Plus: Here’s how Insmed grows to be the next $100 billion biotech

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

FDA’s gene therapy turmoil, and an alternative model for funding research

Adam's Take Adam Feuerstein

STAT Plus: What’s next for Sarepta Therapeutics with gene therapy under fire?

Exclusive Jason Mast and Adam Feuerstein

STAT Plus: Top gene therapy regulator forced out at FDA

First Opinion Christine McSherry

STAT Plus: Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys

Biotech Adam Feuerstein and Jason Mast

STAT Plus: After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Lab Dish Paul Knoepfler

STAT Plus: RFK Jr. acknowledges receiving unproven stem cell treatment from an Antigua clinic

Biotech Jason Mast

STAT Plus: FDA reassures rare disease advocates that ‘being flexible’ is plan for gene therapy

Health Jason Mast

STAT Plus: Day 3 at ASGCT: Vinay Prasad speculation, screening newborns, promising data

Biotech Jason Mast

STAT Plus: At gene therapy meeting, no one wants to talk about the Vinay Prasad (not) in the room

In the Lab Jason Mast

STAT Plus: Day 1 at ASGCT: Missing scientists, a gene editing failure, and a gene editing first

In the Lab Megan Molteni

Prenatal genetic therapy for SMA shows promise in a mouse study

In the Lab Megan Molteni

STAT Plus: Scientific societies call for a moratorium on using CRISPR to create genetically modified children

Opinions+ Kelly Banas and Eric B. Kmiec

STAT Plus: Biotech investors: Stop expecting CRISPR science to make big leaps

Opinions+ Tim Hunt

STAT Plus: Impatient about cell and gene therapy? Progress in biotech is not always linear

Morning Rounds O. Rose Broderick

WHO calls for help on TB outbreak

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

Zealand’s obesity strategy and Immunovant’s curious development plan

Biotech Eric Boodman and Katie Palmer

STAT Plus: Gene therapies and CRISPR drugs slowed by ‘irrational pessimism,’ say scientists forging new paths

Biotech Jason Mast

STAT Plus: Novartis finally delivers gene therapy data in older SMA patients. Will they still want it? 

Biotech Jason Mast

STAT Plus: Prime and Beam, born of same lab, pursuing rival gene-editing treatments

Biotech Jason Mast

STAT Plus: Scribe Therapeutics becomes latest CRISPR company to announce layoffs 

Biotech Jason Mast

STAT Plus: Pfizer kills hemophilia gene therapy deal, imperiling Sangamo

Health Angus Chen

Why bone marrow transplants are becoming less common

First Opinion Rafael Escandon and Arthur L. Caplan

STAT Plus: Gene therapy trials should emphasize transparency, not secrecy

Health Jason Mast

(Your name here) gene therapy: new fund-raising gambit for family with rare disease